{"entity":{"id":"da-novo","kind":"company","name":"Novo Nordisk","aka":[],"tldr":"Novo Nordisk markets GLP-1 medicines for other indications and is testing semaglutide in Alzheimer’s EVOKE trials.","summary":"Diabetes/obesity labels do not equal a dementia indication. EVOKE is investigational. Not investment advice.","asOf":"2026-09-21","links":[{"label":"Novo Nordisk","url":"https://www.novonordisk.com/"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-semaglutide-evoke"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-evoke"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bagsværd","country":"DK","companyType":"pharma","website":"https://www.novonordisk.com/","investors":[],"funding":[]},"route":"/companies/da-novo/","neighbours":{"drug":[{"id":"da-semaglutide-evoke","kind":"drug","name":"Semaglutide (EVOKE programme)","route":"/drugs/da-semaglutide-evoke/"}],"trial":[{"id":"da-trial-evoke","kind":"trial","name":"EVOKE (semaglutide in early Alzheimer’s)","route":"/trials/da-trial-evoke/"}],"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}]}}